---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-067495"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:58:31.815900+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio reports Q1 2025 net loss $15.8M; $138.3M cash; BBI-355 data due H2 2025

## Summary
- Cash, cash equivalents, and short-term investments totaled $138.3M as of March 31, 2025, providing runway into 2027.
- Net loss of $15.8M for Q1 2025 versus $15.4M in Q1 2024; R&D expenses $12.1M ($13.1M Q1 2024), G&A $5.2M ($3.8M).
- BBI-355 Phase 1/2 POTENTIATE trial enrollment ongoing; preliminary clinical proof-of-concept data expected second half 2025.
- Novel Kinesin program: development candidate nomination expected mid-2025, IND filing planned for first half 2026.

## SEC filing metadata
- accession: 0000950170-25-067495
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/0000950170-25-067495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017025067495/bold-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-067495
- JSON: https://secwatch.observer/filing/0000950170-25-067495.json
- Plain text: https://secwatch.observer/filing/0000950170-25-067495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.